leishmania amazonensis

DHQZ 36 is a potent retrograde trafficking inhibitor. It has potent anti-parasite activity. DHQZ 36 inhibits Leishmania amazonensis infection in macrophages (EC50: 13.63 μM).

LQB-118, an orally active compound sourced from sandalwood, demonstrates multiple therapeutic capabilities. It has shown proficiency in inhibiting glioblastoma cell migration and inducing apoptosis. Additionally, LQB-118 can curtail both migration and invasion of prostate cancer cells by modulating the AKT/GSK3β pathway and regulating MMP-9/reck gene expression. The compound is also effective against yeast polysaccharide-induced inflammation in both in vivo and in vitro settings. Notably, LQB-118 specifically triggers ROS-mediated and mitochondrial-dependent apoptosis in Leishmania amazonensis, highlighting its potential in studies focusing on inflammation, infections, and various cancers.

T.cruzi-IN-4 (Compound 21) is an antiparasitic agent. It suppresses both the trypomastigote and amastigote forms of Trypanosoma cruzi, achieving an IC50 of 0.033 μM (after 120 hours). Additionally, T.cruzi-IN-4 hinders the promastigote and amastigote forms of Leishmania infantum, with IC50 values of 28.74 and 61.82 μM respectively, and it inhibits the promastigote form of Leishmania amazonensis with an IC50 of 18.38 μM.

PT4 is a treatment agent for Cutaneous leishmaniasis (CL). PT4 decreases of mitochondrial membrane potential and increases reactive oxygen species production, therefore leads to parasite death. PT4 is effective against both species of Leishmania. The IC50 values of PT4 against L. amazonensis and L. braziliensis are 125.18 and 233.18 μM , respectively. PT4 also shows potent anti-inflammatory activity in vivo [1].